Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

HISTORICAL FACTS: Zacks scr | History Defined

PNDHF: Insider Participation in Private Placement Underscores Management's Confidence in Company Prospects

By M. Marin OTCQB:PNDHF | TSX.V:POND READ THE FULL PNDHF RESEARCH REPORT

Benzinga

FRXIF: A Stock On the Cusp of Catching On Fire

By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT

Benzinga

CLMEF: An Energy Company with an Enticing Yield

By Brad Sorensen, CFA OTC:CLMEF

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

VSQTF: Q2 Report at Victory Square Shows Rapid Growth at IV Hydreight and XR Immersive

By Lisa Thompson OTC:VSQTF READ THE FULL VSQTF RESEARCH REPORT

Benzinga

GBLI: INITIATION: Smallcap specialty property & casualty insurer entering a new and focused growth phase. The company operates in specialty areas primarily in excess and surplus lines.

By Thomas Kerr, CFA NYSE:GBLI READ THE FULL GBLI RESEARCH REPORT

Benzinga

MCVT: An Old-Fashioned Money Maker in Volatile Times

By Brad Sorensen, CFA NASDAQ:MCVT

Benzinga

ALLR: A Precision Undertaking

By John Vandermosten, CFA NASDAQ:ALLR READ THE FULL ALLR RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

Benzinga

ACOGF: Bioequivalence Complete

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga

XTMIF: XTM Increases Revenues 224% in Q2 with a Fully Opened Hospitality Industry in Canada

By Lisa Thompson OTC:XTMIF READ THE FULL XTMIF RESEARCH REPORT

Benzinga

ALQGC: FRESH Results in November

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Benzinga

RFHRF: Renforth Resources Continued to Advance Surimeau with a Spring Prospecting Campaign & a Summer Follow-Up Program Leading to Lalonde's Mineralized Strike Expanding from 2.5km to 9km.

By Steven Ralston, CFA OTC:RFHRF READ THE FULL RFHRF RESEARCH REPORT

Benzinga

VIVXF: OxC-beta Approved in China…

By David Bautz, PhD MKT:TICKER READ THE FULL VIVXF RESEARCH REPORT

Benzinga

SYTA: UPDATE: Siyata reports 2022 2nd quarter financial results and updates investor community on new distribution and partnership efforts.

By Thomas Kerr, CFA NASDAQ:SYTA READ THE FULL SYTA RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

STKH: UPDATE: The company reported 2nd quarter 2022 results which were largely inline with our estimates. The company also made a significant name change and rebranding during the quarter.

By Thomas Kerr, CFA NASDAQ:STKH READ THE FULL STKH RESEARCH REPORT

Benzinga

ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT

Benzinga

VQS: Outlook Strong as Active Client Base Reaches Record Levels, Operations Resume in Key Verticals

By M. Marin NASDAQ:VQS | TSX:VQS READ THE FULL VQS RESEARCH REPORT

Benzinga

NEXCF: Nextech Continues its Transition to AR and Metaverse Pure Play in Q2

By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs.

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

NHWK: Scorpion Grand Opening 3Q:22

By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT

Benzinga

GTRIF: GTI Energy Ltd Focused on Acquiring and Advancing U.S.-based Uranium ISR Projects

By Steven Ralston, CFA OTC:GTRIF | ASX:GTR READ THE FULL GTRIF RESEARCH REPORT

Benzinga

MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

NOVN: EPI Revenue Trends Are Strong

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

BTAI: SERENITY III Trial to Initiate in 2H22…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga

DYAI: Dapibus on the Menu

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.